TSC1 and colorectal cancer: This study identifies TSC1 as a prognostic biomarker and defines the TSC1/mTORC1/glycosylation axis as a potential therapeutic target to improve immune suppression in colorectal cancer, providing fundamental insights for the development of precision immunotherapy strategies.